Novartis Sets Out Next Steps For Sandoz Spinoff
Parent Company Reveals Details Of Upcoming Process As Board Approves Separation
Following unanimous approval by the Novartis board of directors for the spinoff of Sandoz, the generics and biosimilars giant’s parent company has set out some key dates in the lead-up to separation later this year.
